Last updated on June 2017

Open-Label Multi-Center Two-Part Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors


Brief description of study

This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg tazemetostat that contains approximately 400 µCi of [14C]-labeled tazemetostat in three subjects with B-cell lymphomas.

Clinical Study Identifier: NCT03010982

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Harry Miao, MD, PhD

The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, United Kingdom
  Connect »

Harry Miao, MD, PhD

Royal Liverpool and Broadgreen University Hospital Trust
Liverpool, United Kingdom
  Connect »